1. Home
  2. LUNG vs ONCY Comparison

LUNG vs ONCY Comparison

Compare LUNG & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$2.53

Market Cap

97.1M

Sector

Health Care

ML Signal

HOLD

Logo Oncolytics Biotech Inc.

ONCY

Oncolytics Biotech Inc.

HOLD

Current Price

$0.43

Market Cap

80.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LUNG
ONCY
Founded
1995
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Pharmaceuticals and Biotechnology
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
97.1M
80.5M
IPO Year
2020
2002

Fundamental Metrics

Financial Performance
Metric
LUNG
ONCY
Price
$2.53
$0.43
Analyst Decision
Buy
Buy
Analyst Count
5
6
Target Price
$3.70
★ $4.20
AVG Volume (30 Days)
279.2K
★ 1.2M
Earning Date
10-27-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 7.64
N/A
EPS
N/A
★ N/A
Revenue
★ $90,497,000.00
N/A
Revenue This Year
$0.06
N/A
Revenue Next Year
$8.58
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 8.01
N/A
52 Week Low
$1.13
$0.44
52 Week High
$2.66
$1.30

Technical Indicators

Market Signals
Indicator
LUNG
ONCY
Relative Strength Index (RSI) 77.09 25.32
Support Level $1.20 N/A
Resistance Level N/A $0.89
Average True Range (ATR) 0.13 0.05
MACD 0.07 0.00
Stochastic Oscillator 85.71 1.09

Price Performance

Historical Comparison
LUNG
ONCY

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

About ONCY Oncolytics Biotech Inc.

Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.

Share on Social Networks: